Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Jeff Farrow Becomes New CFO and CSO at Tarsus
Tarsus Pharmaceuticals has appointed Jeff Farrow as both Chief Financial Officer and Chief Strategy Officer, effective immediately. Farrow replaces Leo Greenstein, who had been CFO since 2020 but is leaving the company to pursue other professional interests. Farrow has over…
Bausch + Lomb Launches Ovd in the U.S.
Bausch + Lomb Corporation has recently launched the StableVisc™ cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc™ Viscoelastic System in the United States. These new products offer eye surgeons dual-action protection during cataract surgery, expanding the range of options available.…
Ocumension Submits NDA for Zerviate in China
Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) seeking approval for commercialization of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. The intended use of Zerviate is for the treatment of ocular…
Tepezza Improves Proptosis in Patients With Chronic TED
Horizon Therapeutics has announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA for the treatment of adults with chronic thyroid eye disease (TED) and low CAS, a measure of disease activity.…
Apellis’ Syfovre for Treatment of GA Approved by FDA
The FDA has approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This marks the first time that patients with GA have an FDA-approved treatment option, which is a significant milestone…
J&J announced new products at the AAO annual meeting
Johnson & Johnson Vision announced a series of new products and innovations at the 2019 American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco, CA, USA. The company announced the US Food & Drug Administration (FDA) approval of the…
VSY Biotech Signs Agreement With WAKAMOTO Pharma
Leinfelden – Echterdingen, Germany March 19, 2021, VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics, announced today an agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. (hereinafter refer to…
Updates On Central Serous Chorioretinopathy
Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…
Alcon Signs $770 Million Deal to Acquire Aerie Pharma. I OBN
Swiss eye care company Alcon AG announced on Tuesday that it has entered into a definitive merger agreement with Aerie Pharmaceuticals (AERI.O) in a deal worth around $770 million. This deal complements Alcon’s dedication to the ophthalmic pharmaceutical industry and is…
Selagine and Grifols Team Up for DED Eye Drops
Selagine announced a global collaboration with Grifols to develop and commercialize immunoglobulin eye drops for dry eye disease. Financial terms of the agreement were not disclosed. As per the agreement, Selagine will receive an upfront payment and annual collaboration fee,…